Current Insights in the Development of Efficacious Vaccines Against RSV-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Current Insights in the Development of Efficacious Vaccines Against RSV

Published:2020-07-17 Issue: Volume:11 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Soto Jorge A.,Stephens Laura M.,Waldstein Kody A.,Canedo-Marroquín Gisela,Varga Steven M.,Kalergis Alexis M.

Funder

Fondo Nacional de Desarrollo Científico y Tecnológico

Instituto Milenio en Inmunología e Inmunoterapia

National Institutes of Health

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference63 articles.

1. Defining the epidemiology and burden of severe Respiratory Syncytial Virus infection among infants and children in Western Countries;Bont;Infect Dis Ther.,2016

2. WHO consultation on Respiratory Syncytial Virus vaccine development report from a World Health Organization Meeting held on 23–24 March 2015;Modjarrad;Vaccine.,2016

3. Global burden of acute lower respiratory infections due to Respiratory Syncytial Virus in young children: a systematic review and meta-analysis;Nair;Lancet.,2010

4. Respiratory Syncytial Virus infection in elderly and high-risk adults;Falsey;N Engl J Med.,2005

5. Respiratory Syncytial Virus disease: update on treatment and prevention;Krilov;Exp Rev Anti Infect Ther.,2011

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study;Vaccine;2024-12

2. Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study;The Lancet Infectious Diseases;2024-09

3. Exploring the development of a promising mucosal adjuvant vaccine for human respiratory syncytial virus (RSV) infection;Journal of King Saud University - Science;2024-09

4. A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months;Open Forum Infectious Diseases;2024-08-08

5. Systemic prime mucosal boost significantly increases protective efficacy of bivalent RSV influenza viral vectored vaccine;npj Vaccines;2024-06-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3